CuroNZ Gets Infusion Of Funds To Test Peptides For Treating MS
This article was originally published in PharmAsia News
Executive Summary
New Zealand's CuroNZ, a biotech startup, has received just more than $451,000 from the U.S. National Multiple Sclerosis Society to begin pre-clinical studies of neural regeneration peptides for treating the disease.